fludarabine has been researched along with Neutropenia in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (16.67) | 18.2507 |
| 2000's | 34 (47.22) | 29.6817 |
| 2010's | 22 (30.56) | 24.3611 |
| 2020's | 4 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Avivi, I; Bot, A; Bouabdallah, K; Dong, J; Dührsen, U; Houot, R; Kerber, A; Kersten, MJ; Kim, JJ; Kuruvilla, J; Lugtenburg, PJ; Minnema, MC; Plaks, V; Rossi, JM; Sherman, M; Song, KW; Thieblemont, C; Topp, MS; van Meerten, T; Vardhanabhuti, S; Wermke, M; Zheng, Y | 1 |
| Cao, J; Cheng, H; Gao, X; Jiao, J; Li, D; Li, W; Li, Z; Liu, H; Ma, Y; Qin, Y; Sang, T; Sang, W; Shi, M; Song, X; Sun, C; Sun, H; Sun, K; Wang, Y; Wu, M; Xu, K; Xu, L; Yan, D; Yan, Z; Yang, J; Yao, M; Zeng, L; Zhang, B; Zheng, J; Zhu, F | 1 |
| Chen, A; Hayes-Lattin, B; Maziarz, RT; Murphree, C; Nagle, SJ; Nemecek, E; Raess, PW; Schachter, L | 1 |
| Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M | 1 |
| Buxhofer-Ausch, V; Geissler, K; Girschikofsky, M; Gleixner, K; Herndlhofer, S; Hoermann, G; Jaeger, U; Knoebl, P; Kundi, M; Machherndl-Spandl, S; Poehnl, R; Sliwa, T; Sperr, WR; Strecker, K; Valent, P; Weltermann, A | 1 |
| Bouvet, E; Cazin, B; Coiffier, B; Laurent, G; Michallet, AS; Mosser, L; Oberic, L; Salles, G; Schlaifer, D; Ysebaert, L | 1 |
| Abella, E; Abrisqueta, P; Bobillo, S; Bosch, F; Calvo, X; Carbonell, F; Constants, M; Delgado, J; Escoda, L; Ferrà, C; Ferrer, S; García-Marco, JA; González, M; González, Y; González-Barca, E; Jarque, I; Montoro, JB; Montserrat, E; Monzó, E; Muntañola, A; Terol, MJ; Villamor, N | 1 |
| Blijlevens, NM; de Haan, AF; Donnelly, JP; Herbers, AH; van der Velden, WJ | 1 |
| Bacigalupo, A; Ballerini, F; Clavio, M; Cruciani, F; De Astis, E; Di Grazia, C; Galaverna, F; Ghiggi, C; Ghiso, A; Gobbi, M; Guolo, F; Lemoli, RM; Lovera, D; Marani, C; Miglino, M; Minetto, P; Mitscheunig, L; Pastori, G; Raiola, AM; Varaldo, R | 1 |
| Davis, J; Haut, P; Hayashi, R; Kothari, A; Loechelt, BJ; Murray, L; Ngwube, A; Shenoy, S | 1 |
| Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G | 1 |
| Bloor, A; Blundell, J; Fegan, C; Gribben, JG; Hamblin, M; Hillmen, P; Hockaday, A; Howard, DR; McParland, L; Munir, T; Pettitt, A; Phillips, D; Pocock, C; Rawstron, AC; Varghese, A | 1 |
| Chiusolo, P; De Padua, L; Efremov, DG; Garzia, M; Innocenti, I; Laurenti, L; Leone, G; Piccirillo, N; Sica, S; Sorà, F; Tarnani, M; Zini, G | 1 |
| Gil, L; Komarnicki, M; Kozlowska-Skrzypczak, M; Mol, A; Poplawski, D; Styczynski, J | 1 |
| Branagan, AR; Emmanouilides, C; Frankel, SR; Gregory, SA; Ioakimidis, L; Kimby, E; Lister, A; Matous, J; Morel, P; Patterson, CJ; Soumerai, JD; Treon, SP; Turnbull, B; Wasi, P | 1 |
| Boyiadzis, M; Butchko, A; Foon, KA; Laman, A; Land, SR; Lenzer, D; Marks, S; Meisner, D; Pietragallo, L; Raptis, A; Schaefer, P; Sulecki, M; Tarhini, A | 1 |
| Aksoy, S; Dizdar, O; Harputluoğlu, H; Hayran, M | 1 |
| Brown, PV; Conneally, E; Delaney, E; Hayat, A; Lawler, M; Liptrot, S; McCann, SR; McGuckin, S; O'Brien, D; O'Rourke, P; Quinn, F; Vandenberghe, E | 1 |
| Burgaleta, C; Cabrera, C; Canales, M; De la Serna, J; Fernández de Sevilla, A; Gonzalez, M; Martínez, R; Martínez-López, J; Montalbán, C; Monteagudo, MD; Paz-Carreira, J; Peñalver, FJ; Peñarrubia, MJ; Prieto, E; Queizán, JA; Rapado, I; Rivero, A; Salar, A; Sánchez-Godoy, P; Tomás, JF | 1 |
| Carney, D; Gill, S; Januszewicz, H; Prince, HM; Ritchie, D; Seymour, JF; Westerman, D; Wolf, M | 1 |
| Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
| Chiang, R; Earp, J; Gootenberg, JE; Keegan, P; Lemery, SJ; McDougal, A; Pazdur, R; Pilaro, A; Rothmann, MD; Yang, J; Zhang, J; Zhao, H | 1 |
| Abramson, J; Brown, JR; Dalton, V; Freedman, AS; Hochberg, E; Kuang, Y; McDonough, SM; Mikler, E; Neuberg, D; Reynolds, H; Ritz, J; Thompson, C; Werner, L | 1 |
| Baldini, L; Federico, M; Ferrario, A; Goldaniga, MC; Luminari, S; Mannina, D; Marcheselli, L; Mazza, P; Merli, F; Russo, M; Stelitano, C | 1 |
| Bergmann, M; Berrebi, A; Böttcher, S; Bühler, A; Busch, R; Caligaris-Cappio, F; Catalano, J; Cazin, B; Döhner, H; Eichhorst, BF; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, M; Hensel, M; Hess, G; Hopfinger, G; Jäger, U; Kneba, M; Mayer, J; Mendila, M; Ritgen, M; Seymour, JF; Staib, P; Stilgenbauer, S; Trneny, M; von Grünhagen, U; Wendtner, CM; Westermann, A; Winkler, D; Zenz, T; Zinzani, PL | 1 |
| Canales, M; de la Serna, J; de Oña, R; de Sevilla, AF; Martínez, R; Martínez-López, J; Montalbán, C; Paz-Carreira, J; Rapado, I; Rivero, A; Sánchez-Godoy, P; Tomás, JF | 1 |
| Jordheim, LP | 1 |
| Einberger, C; Fleiss, K; Fonatsch, C; Gaiger, A; Gruber, M; Hauswirth, AW; Heintel, D; Jäger, U; Porpaczy, E; Shehata, M; Skrabs, C; Thalhammer, R; Vanura, K | 1 |
| Badoux, X; Burger, J; Estrov, Z; Faderl, S; Ferrajoli, A; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Parikh, SA; Wang, X; Wierda, WG | 1 |
| Cao, JN; Fan, Y; Gu, KS; Guo, Y; Hong, XN; Li, XQ; Liu, XJ; Wang, CF; Wu, XH; Zhang, J | 1 |
| Aurran-Schleinitz, T; Dartigeas, C; Feugier, P; Leprêtre, S; Letestu, R; Van Den Neste, E; Ysebaert, L | 1 |
| Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J | 1 |
| Catovsky, D; Cocks, K; Crofts, S; Else, M; Richards, SM; Smith, AG; Wade, R | 1 |
| Ajana, F; Ettahar, N; Legout, L; Massongo, M; Patoz, P; Rose, C; Senneville, E | 1 |
| Brettman, L; Cooper, MR; Freter, CE; Mercier, RJ; Mitchell, BS; Rai, KR; Santábarbara, P; Stadtmauer, EA; Wacker, B | 1 |
| Aulitzky, WE; Diehl, V; Engert, A; Hallek, M; Hensel, M; Herold, M; Hinke, A; Huhn, D; Klein, SK; Knauf, WU; Rehwald, U; Reiser, M; Schulz, H | 1 |
| Eagleton, H; Hatton, C; Leyden, K; Littlewood, T; Pearson, D; Pillai, N; Sternberg, A; Turner, S | 1 |
| Aliff, TB; Frankel, SR; Horgan, D; Jurcic, JG; Kossman, SE; Lamanna, N; Maslak, PG; Scheinberg, DA; Weiss, MA | 1 |
| Abbasi, MR; Sarta, C; Sparano, JA; Wiernik, PH | 1 |
| Annunziata, M; Copia, C; D'Amico, MR; De Simone, M; Ferrara, F; Palmieri, S; Pocali, B; Schiavone, EM; Vecchio, LD | 1 |
| Chizuka, A; Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Tajima, K; Takaue, Y; Taniguchi, S; Usubuchi, N | 1 |
| Bucher, C; Buser, AS; Gratwohl, A; Heim, D; Passweg, JR; Tichelli, A | 1 |
| Bowen, A; Catovsky, D; Hendry, L; Matutes, E; Swansbury, J | 1 |
| Buser, A; Gratwohl, A; Heim, D; Kostova, G; Passweg, J; Tichelli, A | 1 |
| Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A | 1 |
| Adler, SS; Enschede, SH; Gregory, SA; Porter, C; Rao, R; Shammo, JM; Venugopal, P | 1 |
| Alexaki, P; Christakis, GB; Megalakaki, A; Perlorentzou, S; Zarkadis, IK | 1 |
| Beri, R; Chen, HY; Chunduri, S; Dobogai, LC; Hoffman, R; Jessop, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y | 1 |
| Austin, HA; Balow, JE; Boumpas, DT; Chitkara, P; Fleisher, T; Illei, GG; Klippel, JH; Kuroiwa, T; Schlimgen, R; Tisdale, JF; Yarboro, CH | 1 |
| Buzyn, A; Candon, S; Casadevall, N; Hummel, A; Ittah, M; Lavie, F; Louache, F; Mariette, X; Soumelis, V; Terrier, B; Tourneur, L | 1 |
| Brugiatelli, M; Federico, M; Liberati, M; Marcheselli, R; Merli, F; Orsucci, L; Pozzi, S; Sacchi, S; Tucci, A; Vallisa, D | 1 |
| León-Mateos, A; Sánchez-Aguilar, D; Toribio, J | 1 |
| Baccarani, M; Derenzini, E; Fanti, S; Fina, M; Musuraca, G; Perrotti, A; Stefoni, V; Tani, M; Vitolo, U; Zinzani, PL | 1 |
| Hamdi, S; Huguet, F; Laporte, F; Oksman, F | 1 |
| Escudier, SM; Seymour, JF | 1 |
| Andreeff, M; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Pierce, S; Robertson, B | 1 |
| Bendandi, M; Tabanelli, M; Tura, S; Zinzani, PL | 1 |
| Woodcock, BE | 1 |
| Amess, J; Ganjoo, RK; Johnson, PW; Lim, J; Lister, TA; Norton, AJ; Pigaditou, A; Rohatiner, AZ; Rossi, A; Whelan, JS | 1 |
| Arning, M; Schneider, W; Südhoff, T | 1 |
| Frewin, RJ; Provan, D; Smith, AG | 1 |
| Hoskin, PJ; Kanegaonkar, R; Mahadevan, A | 1 |
| Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Talpaz, M | 1 |
| Juliusson, G | 1 |
| Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P | 1 |
| Costello, C; Shah, S; Stern, SC | 1 |
| Cabanillas, F; Dang, NH; Hagemeister, FB; Lee, MS; McAda, N; McLaughlin, P; Pate, O; Preti, AH; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A | 1 |
| Brittinger, G; Busch, R; Döhner, H; Emmerich, B; Fostitsch, HP; Franke, A; Freund, M; Hallek, M; Herold, M; Hiddemann, W; Knauf, W; Kröber, A; Kuse, R; Nerl, C; Schmitt, B; Schriever, F; Sezer, O; Thiel, E; Wendtner, CM; Wilhelm, M | 1 |
| Fox, RM; Grigg, AP; Seymour, JF; Szer, J | 2 |
| Anagnostopoulos, A; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Kiamouris, C; Mantzios, G; Nicolaides, C; Papageorgiou, E | 1 |
| Albitar, M; Binet, JL; Brettman, L; Byrd, J; Flinn, I; Hillmen, P; Jain, V; Keating, MJ; Rai, KR; Santabarbara, P; Wacker, B | 1 |
5 review(s) available for fludarabine and Neutropenia
| Article | Year |
|---|---|
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Humans; Lymphoma; Neutropenia; Opportunistic Infections; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2009 |
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
Topics: Agammaglobulinemia; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Neutropenia; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2012 |
[Cryptococcal osteomyelitis in a patient with a lymphocytic leukemia treated with fludarabine-cyclophosphamide-rituximab].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcosis; Cryptococcus neoformans; Cutaneous Fistula; Cyclophosphamide; Diabetes Mellitus, Type 2; Female; Fungemia; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Diseases, Fungal; Neutropenia; Opportunistic Infections; Osteolysis; Osteomyelitis; Rituximab; Vidarabine | 2013 |
Prophylactic strategies to meet infectious complications in fludarabine-treated CLL.
Topics: Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Granulocyte Colony-Stimulating Factor; Humans; Immunoglobulins, Intravenous; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Opportunistic Infections; Salvage Therapy; Vidarabine | 1997 |
Complications in the treatment of CLL with purine analogues.
Topics: Anemia, Hemolytic, Autoimmune; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Purine Nucleosides; Vidarabine | 1997 |
38 trial(s) available for fludarabine and Neutropenia
| Article | Year |
|---|---|
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Biological Products; Biomarkers; Cyclophosphamide; Cytokine Release Syndrome; Drug Therapy, Combination; Female; Humans; Immunotherapy, Adoptive; Leukapheresis; Levetiracetam; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Nervous System Diseases; Neutropenia; Propensity Score; Vidarabine; Young Adult | 2021 |
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Topics: Adult; Aged; Anemia; Antigens, CD19; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; CD4-CD8 Ratio; Confidence Intervals; Cyclophosphamide; Cytokine Release Syndrome; Female; Glycolysis; Humans; Ifosfamide; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Progression-Free Survival; Receptors, Chimeric Antigen; Recurrence; T-Lymphocytes; Thrombocytopenia; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Pharmacological; Chlorambucil; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Non-Randomized Controlled Trials as Topic; Progression-Free Survival; Recurrence; Safety; Thrombocytopenia; Treatment Outcome; Vidarabine | 2021 |
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Vidarabine | 2017 |
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2013 |
Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
Topics: Acute Disease; Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Melphalan; Myeloablative Agonists; Neutropenia; Prospective Studies; Risk; Siblings; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2015 |
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Adhesion Molecules; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Prospective Studies; Radioimmunotherapy; Radioisotopes; Rhenium; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2015 |
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Neutropenia; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vidarabine | 2017 |
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Topics: Administration, Oral; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neutropenia; Remission Induction; Vidarabine | 2008 |
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neutropenia; Pneumonia; Prospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.
Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Rituximab; Thrombocytopenia; Vidarabine | 2010 |
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Italy; Lymphoma, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine; Young Adult | 2011 |
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Neutropenia; Rituximab; Severity of Illness Index; Treatment Outcome; Vidarabine | 2010 |
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Risk Factors; Rituximab; Smith-Magenis Syndrome; Thrombocytopenia; Vidarabine | 2011 |
Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Survival Rate; Thrombocytopenia; Treatment Outcome; Vidarabine; Vomiting | 2012 |
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Dose-Response Relationship, Immunologic; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Tumor Lysis Syndrome; Vidarabine | 2012 |
Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Fatigue; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Quality of Life; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; Vidarabine; Vomiting | 2012 |
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, T-Cell; Male; Neutropenia; Opportunistic Infections; Pilot Projects; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine | 2002 |
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cerebral Hemorrhage; Chills; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome; Vidarabine | 2003 |
Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2003 |
High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Disease Progression; Drug Therapy; Female; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Vidarabine | 2004 |
Cytopenia and hematopoietic recovery after low intensity conditioning transplants.
Topics: Adult; Female; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Survival Analysis; Thrombocytopenia; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Neoplasm Staging; Neutropenia; Patient Selection; Recurrence; Treatment Outcome; Vidarabine | 2005 |
Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutropenia; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
Topics: Adult; Aged; CD4 Lymphocyte Count; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Lupus Nephritis; Lymphopenia; Male; Middle Aged; Neutropenia; Pilot Projects; Proteinuria; Treatment Outcome; Vidarabine | 2007 |
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gene Rearrangement; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thrombocytopenia; Time Factors; Treatment Outcome; Vidarabine | 2007 |
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Radioimmunotherapy; Survival Analysis; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2008 |
Fludarabine in low-grade lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Vidarabine | 1993 |
Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fever; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neutropenia; Vidarabine | 1997 |
Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Mitoxantrone; Neoplasm Staging; Neutropenia; Rituximab; Vidarabine | 2000 |
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome; Vidarabine | 2001 |
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobilization; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Risk Factors; Survival Analysis; Treatment Outcome; Vidarabine | 2001 |
Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Vidarabine | 2002 |
Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Remission Induction; Survival Analysis; Survival Rate; Vidarabine | 2002 |
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Demography; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome; Vidarabine | 2002 |
29 other study(ies) available for fludarabine and Neutropenia
| Article | Year |
|---|---|
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Female; Ferritins; Humans; Immunotherapy, Adoptive; Infections; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Retrospective Studies; Thrombocytopenia; Vidarabine; Young Adult | 2021 |
First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Comorbidity; Creatinine; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multivariate Analysis; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Rituximab; Vidarabine | 2013 |
Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients.
Topics: Adult; Aged; Bacteremia; C-Reactive Protein; Citrulline; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mucositis; Myeloablative Agonists; Neutropenia; Prospective Studies; Transplantation Conditioning; Vidarabine | 2014 |
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Diarrhea; Drug Administration Schedule; Drug Evaluation; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult | 2014 |
Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Carmustine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Neutropenia; Prospective Studies; Risk Factors; Rituximab; Vidarabine; Young Adult | 2009 |
Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Rituximab; Treatment Outcome; Vidarabine | 2009 |
Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2009 |
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
Topics: Adult; Aged; Alleles; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Early Termination of Clinical Trials; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Variation; Haplotypes; Humans; Infections; Lymphoma, Follicular; Lymphopenia; Male; Mannose-Binding Lectin; Middle Aged; Multicenter Studies as Topic; Neutropenia; Prospective Studies; Risk; Rituximab; Spain; Vidarabine; Young Adult | 2009 |
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Pancytopenia; Prevalence; Retrospective Studies; Thrombocytopenia; Time Factors; Vidarabine | 2010 |
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD20; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Fever; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neutropenia; Pneumonia; Treatment Outcome; United States; United States Food and Drug Administration; Vidarabine | 2010 |
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine Kinase; DNA Mutational Analysis; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphoma, Follicular; Lymphopenia; Neutropenia; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Vidarabine | 2011 |
Further evidences for pharmacogenetic assessment of nucleoside analogue-treated patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine Kinase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Follicular; Lymphopenia; Neutropenia; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Treatment Outcome; Vidarabine | 2011 |
Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Drug Monitoring; Female; Granulocyte Colony-Stimulating Factor; Hematologic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Pilot Projects; Recombinant Proteins; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine | 2011 |
Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Leukemia, T-Cell; Male; Middle Aged; Neutropenia; Vidarabine | 2003 |
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Pentostatin; Thrombocytopenia; Treatment Outcome; Vidarabine | 2003 |
Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Child; Child, Preschool; Cladribine; Female; Fever; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2004 |
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; CD4-CD8 Ratio; Dexamethasone; Female; Humans; Immunosuppression Therapy; Infections; Interferons; Lymphoma; Male; Middle Aged; Mitoxantrone; Neutropenia; Vidarabine | 2005 |
Central line-related bacteraemia due to Roseomonas mucosa in a neutropenic patient with acute myeloid leukaemia in Piraeus, Greece.
Topics: Acute Disease; Adult; Amikacin; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bacteremia; Base Sequence; Catheterization, Central Venous; Cytarabine; Humans; Leukemia, Myeloid; Male; Methylobacteriaceae; Molecular Sequence Data; Neutropenia; Penicillanic Acid; Phylogeny; Piperacillin; Piperacillin, Tazobactam Drug Combination; RNA, Bacterial; RNA, Ribosomal, 16S; Vidarabine | 2006 |
Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Cell Activating Factor; B-Lymphocytes; Bone Marrow; Cell Lineage; Cells, Cultured; Cyclophosphamide; Cytokines; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lymphopoiesis; Middle Aged; Myelopoiesis; Neutropenia; Rituximab; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2007 |
[Ulcers in a patient with chronic lymphocytic leukemia].
Topics: Antimetabolites, Antineoplastic; Ear Diseases; Ear, External; Hand Dermatoses; Herpes Simplex; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Skin Ulcer; Vidarabine | 2007 |
Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Granulocytes; Humans; Hypoglycemic Agents; Leukocyte Count; Lymphoma, B-Cell, Marginal Zone; Male; Metformin; Neutropenia; Splenic Neoplasms; Vidarabine | 2008 |
Acute leukemia complicating bone marrow hypoplasia in an adult with Shwachman's syndrome.
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Neutropenia; Pancreatic Diseases; Syndrome; Vidarabine | 1993 |
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine | 1994 |
Prolonged bone marrow aplasia of refractory prolymphocytoid variant of B-cell chronic lymphocytic leukemia related to fludarabine treatment.
Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukopenia; Male; Middle Aged; Neutropenia; Vidarabine | 1994 |
Cytopenia and fludarabine.
Topics: Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Neutropenia; Thrombocytopenia; Vidarabine | 1993 |
Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 8; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia; Trisomy; Vidarabine | 1997 |
Third space sequestration increases toxicity of fludarabine--a case report.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Drainage; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pleural Effusion; Sepsis; Vidarabine | 1997 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine | 1999 |
Probable autoimmune neutropenia induced by fludarabine treatment for chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Autoimmune Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Vidarabine | 1999 |